1. Introduction {#sec1}
===============

Migraine is a common neurological disease characterized by unilateral, throbbing recurrent headache, often accompanied by photophobia, phonophobia, or nausea \[[@B1]\]. According to the epidemiological statistics, the prevalence of migraine is 3.3%∼32.6% in female and 0.7%∼16.1% in male \[[@B2]\]. At the same time, it costs between 6.5 and 17 billion dollars annually in the USA which severely burdened individuals and society \[[@B3], [@B4]\]. In the Global Burden of Disease Survey 2010, migraine ranked as the 3rd most prevalent disorder and 7th highest specific cause of disability worldwide \[[@B5], [@B6]\]. The standard treatments for migraine include nonsteroidal anti-inflammatory drugs, antiepileptic drugs, ergotamines, and triptans. However, these pharmacotherapies were often accompanied with undesirable adverse effects \[[@B7]\], such as fatigue, sleep disturbance, nausea, and vomiting \[[@B8]\] which lead to poor compliance of patients. Therefore, more and more patients are seeking for effective nonpharmacological alternative treatments.

Acupuncture, an important method in Traditional Chinese Medicine, is widely used in clinical practice as a treatment for migraine. It is reported that acupuncture was one of the most common complementary therapies in worldwide \[[@B9]\]. In German-speaking countries, acupuncture has high utilization and is one of the most primarily used methods to relieve pain \[[@B10]\]. Now, it is increasingly accepted in western countries as an alternative treatment for migraine and other pain conditions \[[@B11]\]. The results of clinical studies have demonstrated that acupuncture is an effective and safe therapeutic approach to treat migraine \[[@B12]--[@B14]\]. With the development of evidence-based medicine, numerous systematic reviews (SRs) have been conducted to investigate the effectiveness and safety of acupuncture for migraine. However, the results of these SRs often have limitations which may lower the quality of conclusions and mislead the patients, clinical doctors, and policy makers.

Overviews of SRs, a method to evaluate the quality of evidence \[[@B15]\], is becoming more and more prevalent in evidence-based medicine \[[@B16]\]. The overview is a comprehensive approach to reassess the quality of SRs by collecting the information of relevant SRs dealing with the same disease or health problem \[[@B17]\]. While SR has always been regarded as one of the most important sources of high quality and reliable information in the evidence-based medicine \[[@B18]\], there are many factors in the evaluation process which can decrease the quality of SRs, such as incomprehensive source of literature, inadequate evaluation method, and publication bias. Overview of SRs comprehensively integrated the evidence of SRs, which contains more information and can provide more high-quality evidence for clinical work.

This is the first overview which comprehensively assessed SRs of acupuncture for migraine with a Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, the Risk of Bias in Systematic reviews (ROBIS), Preferred Reporting Item for Systematic Review and Meta-analysis-Acupuncture (PRISMA-A), and the Grades of Recommendations, Assessment, Development and Evaluation (GRADE). The objective of this overview is to critically assess the quality of relevant SRs and present an objective and comprehensive evaluation on effectiveness and safety of acupuncture for migraine, which can help the public and policy-makers understand whether acupuncture should be recommended as a treatment for migraine.

2. Methods {#sec2}
==========

2.1. Registration {#sec2.1}
-----------------

A predetermined written protocol of this overview was registered in the PROSPERO (International prospective register of systematic overview) database (<https://www.crd.york.ac.uk/PROSPERO/>), registration number: CRD42017077218. This overview was reported in accordance with the guideline of the pilot version checklist with Preferred Reporting Items for overview of systematic reviews (PRIO-harms) \[[@B19]\].

2.2. Ethics {#sec2.2}
-----------

Ethics approval is not required in overview of SRs, since it does not involve individual patient data.

2.3. Inclusion Criteria {#sec2.3}
-----------------------

### 2.3.1. Types of Reviews {#sec2.3.1}

SRs with or without meta-analysis of randomized controlled trials (RCTs) were included in which acupuncture was used as treatment for migraine.

### 2.3.2. Types of Participants {#sec2.3.2}

SRs included RCT recruiting participants diagnosed with migraine according to standard diagnostic criteria (e.g., the International Classification of Headache Disorders released by the International Headache Society or other domestic standards). There was no restriction on the gender, age, race, duration, intensity, condition, and source of the patients.

### 2.3.3. Types of Interventions {#sec2.3.3}

There was no restriction on the types of acupuncture (e.g., body acupuncture, electroacupuncture, auricular acupuncture, warm-acupuncture, and scalp acupuncture).

### 2.3.4. Types of Comparators {#sec2.3.4}

SRs included control groups which were treated with sham-acupuncture, placebo, medicine, and other types of nonpharmaceutical therapy or placed in the waiting list.

### 2.3.5. Types of Outcomes {#sec2.3.5}

The primary outcome was effective rate. Secondary outcomes included intensity, frequency or duration of headache, times of using painkiller, quality of life, recurrent rate, and adverse effects of acupuncture in migraine.

2.4. Exclusion Criteria {#sec2.4}
-----------------------

The SRs were excluded if one of the following criteria was met: did not use the diagnostic criteria of migraine mentioned above; SRs with network meta-analysis or indirect comparison; SRs that included retrospective studies, prospective studies, cross-sectional clinical studies, and case reports; SRs whose data could not be extracted; duplicated publication; review comments.

2.5. Search Strategy {#sec2.5}
--------------------

An electronic literature search was conducted in the MEDLINE, Embase, Cochrane Library, PROSPERO database, Chinese National Knowledge Infrastructure (CNKI), Chinese Biological Medicine (CBM) database, Chinese Science and Technology Periodical Database (SCTJ), and WanFang database, all from the inception to December 2019. Details of search strategy were presented in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}. In addition, reference lists/bibliographies of included studies, study registries, and grey literature, such as dissertations and conference reports, were also searched to avoid missing studies. Besides, the experts in the field were also consulted. No language restrictions were applied.

2.6. Screening {#sec2.6}
--------------

The reviewer (JZ) searched the databases according to the predeveloped standardized search strategy. All the retrieved literatures were imported into Endnote X8. Two reviewers (HY and YXL) independently screened for candidates according to the inclusion and exclusion criteria by reading the title and abstract. Then, the full texts were downloaded for further screening. At the same time, bibliographic references were also reviewed to identify possible SRs. The disagreements were resolved by discussion. If necessary, the discrepancies were resolved by consulting the third reviewer (DLZ).

2.7. Data Extraction {#sec2.7}
--------------------

A data extracted form was predefined, including the characteristics of SRs, such as author, title, published year, sample size, intervention, outcome indicators, quality evaluation method, and conclusion. Data was independently extracted by two reviewers (HY and LJL) using Microsoft Excel. After extraction, the two reviewers (LHS and YXL) cross checked to eliminate mis-entry. Discrepancies were resolved by team discussion or arbitrated by the third reviewer (DLZ).

2.8. Assessment of SRs {#sec2.8}
----------------------

The assessment of included SRs was carried out independently by qualified reviewers who were trained in the Chinese Cochrane Center. Before the evaluation, each topic of the assessment tools was intensively discussed to achieve consensus. After evaluation, two reviewers cross checked the results. Discrepancies were resolved by team discussion or an independent decision form a third reviewer.AMSTAR 2 \[[@B20]\] was used to assess the methodological quality of included SRs. The checklist has 16 items, including 7 critical items (items 2, 4, 7, 9, 11, 13, and 15), which are used to critically assess the validity of an SR. Each item was evaluated as "yes" (a positive result), "partial yes" (partial adherence to the standard), and "no" (no information is provided to rate an item) according to adherence to the standard.The aim of the ROBIS tool is to evaluate the level of bias presented in a systematic review. This tool assesses the level of bias across 4 domains of 2 phases: "study eligibility criteria," "identification and selection of studies," "data collection and study appraisal," and "synthesis and findings". Each domain has signaling questions and a judgment of concerns about risk of bias of the domain, and the results are rated as "high risk," "low risk," or "unclear risk" \[[@B21]\].PRISMA-A statements an extension of PRISMA especially for acupuncture, which was published in 2019 \[[@B22]\]. It consists of a 27-item checklist and a 4-phase flow diagram, aiming to help authors improve the reporting quality of SRs on acupuncture interventions. Seven aspects of SRs include title, abstract, introduction, methods, results, discussion and funding. Response options for each item are "yes," "no," and "not applicable". The completion of each item was presented as a ratio.The quality of primary outcomes of included SRs was evaluated by the GRADE system \[[@B23]\]. The assessment of included SRs was carried out independently by qualified reviewers (JL and DLZ) who were trained in the GRADE Center in China (Lanzhou). The 5 key elements of GRADE influenced the quality of evidence including study limitations, inconsistency of results, indirectness of evidence, imprecision, and reporting bias. The quality of evidences of SRs was rated as "High," "Moderate," "Low," and "Very Low". Evidence based on RCTs began as high quality.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

We retrieved 457 records according to the search strategy. 11 duplicates were excluded by filtration, 445 papers were screened by titles and abstracts. 65 articles were considered eligible, and full-text papers were downloaded. After being reviewed by two reviewers independently, 50 SRs were excluded and 15 SRs \[[@B24]--[@B38]\] were included for further analyses ([Figure 1](#fig1){ref-type="fig"}). The reasons for exclusion are presented in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

3.2. Characteristics of SRs {#sec3.2}
---------------------------

The characteristics of included SRs are presented in [Table 1](#tab1){ref-type="table"}. All the included SRs were published between 2011--2019, 6 of which were published in 2016 \[[@B21], [@B31]--[@B34], [@B36]\]. The number of RCTs in SRs ranged from 2 to 33. 3 SRs were on prophylactic treatment for migraine \[[@B31], [@B33], [@B35]\], 1 SR on acute migraine \[[@B33]\], 1 SR for menstrual migraine \[[@B36]\], 1 SR for migraine without aura \[[@B37]\], and the others did not clearly stated the type of migraine. 11 SRs specified the diagnostic criteria of HIS (International Headache Society) or ICHD (International Classification of Headache Disorders), while 4 SRs \[[@B25], [@B27], [@B28], [@B32]\] did not report the diagnostic criteria. All the 15 SRs performed meta-analysis, 10 out of 15 SRs \[[@B24]--[@B29], [@B31], [@B32], [@B35], [@B38]\] performed subgroup analysis, and only 4 SRs \[[@B30], [@B33], [@B34], [@B36], [@B38]\] conducted sensitivity analysis. The intervention was acupuncture, while comparators were mainly sham acupuncture and medications (ergotamine, ibuprofen, flunarizine, nimodipine, celecoxib, aspirin, somedon, sodium valproate, metoprolol, and topiramate). The outcomes of SRs were effective rate, intensity, and frequency or duration of headache. For the assessment of methodological quality, 2 SRs \[[@B24], [@B29]\] used the Jadad scale, 12 SRs \[[@B25], [@B26], [@B30]--[@B34], [@B36], [@B38]\] used the Cochrane risk of bias tool, and the remaining 1 SR \[[@B27]\] did not report any specific tool but described 6 aspects of quality assessment, including randomization, allocation concealment, blind method, data integrity, selective reporting, and other biases.

3.3. Methodological Quality of Included SRs {#sec3.3}
-------------------------------------------

An overview of methodological quality of included SRs is presented in [Table 2](#tab2){ref-type="table"}. Among the 15 SRs, 14 were rated critically low quality and 1 was rated low quality \[[@B37]\]. Items 2, 3, 7, 10, and 16 were rated particularly low quality. All SRs used satisfactory techniques to assess the risk of bias. Only 1 SR \[[@B37]\] established a prior study protocol and 2 \[[@B28], [@B36]\] reported the funding sources of the included studies. No SR explained the reasons for selection of study types or provided a complete list of excluded studies with reasons. And, few SRs assessed publication bias by a funnel plot.

3.4. Risk of Bias of Included SRs {#sec3.4}
---------------------------------

The ROBIS tool, containing 3 phases with 4 domains, was used to assess the risk of bias of included SRs. Phase 1 assesses the relevance of research question, which is optional and was not performed in our study. [Table 3](#tab3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"} present the assessment of risk of bias of each SR. Domain 1 assessed concerns regarding specification of study eligibility criteria, and 12 of 15 SRs (80%) were rated low risk of bias. Domain 2 assessed concerns regarding methods used to identify and select studies, in which 9 SRs (60%) were in low risk of bias. Domain 3 assessed concerns regarding methods used to collect data and appraise studies, and 11 SRs (73%) were at low risk of bias and 1 \[[@B24]\] unclear risk of bias. Domain 4 assessed concerns regarding the synthesis and findings, and 8 SRs (53%) were rated as low risk of bias. The final phase considered the overall risk of bias of SRs, and 9 SRs (60%) were low risk of bias.

3.5. Reporting Quality of Included SRs {#sec3.5}
--------------------------------------

[Table 4](#tab4){ref-type="table"} presents the overview of PRISMA-A checklist items. 11 out of 15 SRs were adequately reported over 70%. The section of title, abstract, and introduction were all well reported (100%). Though in [Section 2](#sec2){ref-type="sec"}, topic of protocol and registration, search strategy, study selection, data items, risk of bias, and additional analyses were reported inadequately, three topics (study selection, risk of bias across studies, and additional analysis) in [Section 3](#sec3){ref-type="sec"} were reported under 70%. Of all the items, protocol and registration (13.33%), search strategy (33.33%), risk of bias in individual studies (33.33%), and risk of bias across studies (33.33%) accounted for the main reporting limitations. Overall, 4 SRs \[[@B26], [@B36]--[@B38]\] reached over 85% compliance.

3.6. Effectiveness of Acupuncture for Migraine {#sec3.6}
----------------------------------------------

We summarized the outcomes from the included SRs and presented them in [Table 5](#tab5){ref-type="table"}. The evidence suggested that the effective rate of acupuncture was superior to western medicine (risk ratio (RR) = 1.17, 95% confidence interval (CI) = (1.12, 1.22), *P* = 0.71) \[[@B26]\]. Acupuncture had better long-term effective rate for migraine (RR = 4.17, 95% CI (2.80, 6. 20), *P* \< 0.00001) \[[@B34], [@B35]\] and reduced more headache days (standardized mean difference (SMD) = −0.13, 95% CI = (−0.25, −0.02), *P* = 0.02) and the times of using painkiller (SMD = −0.73, 95% CI = (−2.14, 0.69), *P* = 0.31) than western medicine and sham acupuncture, both in short-term and long-term follow-up \[[@B33], [@B35]\]. Besides, acupuncture was more effective in reducing frequency (SMD = −2.18, 95% CI = (−2.61, −1.75), *P* \< 0.00001) and degree of headache (SMD = −1.93, 95% CI = (−2.53, −1.36), *P* = 0.005) than western medicine and sham acupuncture \[[@B31], [@B35]\]. One SR \[[@B25]\] reported more effective rate of acupuncture than Chinese herbal medicine in treating migraine (RR = 1.29, 95% CI = (1.14, 1.45), *P* \< 0.00001).

3.7. Evidence Quality of Included SRs {#sec3.7}
-------------------------------------

We evaluated the quality of primary outcomes extracted from included studies. [Table 6](#tab6){ref-type="table"} shows the level of evidence quality of studies reported effective rate. The high level of evidence quality indicated that the effective rate of acupuncture was superior than western medicine, both in short-term and long-term. The inconsistency and imprecision were the main reasons for downgrading. Significant heterogeneity downgraded inconsistency and imprecision was downgraded because the total sample size did not meet the optimal information size.

3.8. Safety of Acupuncture for Migraine {#sec3.8}
---------------------------------------

Of all the 15 SRs, 8 SRs \[[@B26], [@B30], [@B31], [@B33]--[@B37]\] mentioned the adverse events of acupuncture in the treatment of migraine. 2 SRs \[[@B30], [@B36]\] did not further analyze the safety evaluation due to the small number of studies. 6 SRs \[[@B26], [@B31], [@B33]--[@B35], [@B37]\] concluded that acupuncture treatment had fewer adverse events than medication, which indicated that acupuncture was a safe therapy for migraine.

4. Discussion {#sec4}
=============

4.1. Summary of Main Findings {#sec4.1}
-----------------------------

This is the first overview of SRs that investigate the effectiveness and safety of acupuncture for migraine. We rigorously appraised the published SRs with AMSTAR 2, ROBIS, PRISMA-A, and GRADE. Based on AMSTAR 2, 14 out of 15 SRs were rated critically low quality and 1 was rated low quality. By using the ROBIS tool, 9 SRs were rated low risk bias. With PRISMA-A checklist, we found 11 out of 15 SRs were found adequately reported over 70%. The results of GRADE suggested that acupuncture was is an effective and safe method for migraine.

4.2. Implications for Further Study {#sec4.2}
-----------------------------------

This overview presents several challenges for producers of SRs that should be considered. By using the ROBIS tool, we found that the risk of bias in domain 2 and domain 4 of phase 2 were relatively high. In domain 2, we focused on the risk of bias in identification and selection of studies. The results indicated that the reviewers of SR should pay attention to whether the search includes an appropriate range of databases or electronic sources for published reports. Instead of database searching, the additional methods should also be used to identify relevant reports, including conference reports and clinical trial registration platforms. In domain 4, the risk of bias in synthesis of findings was high. Even though the data was synthesized in all the SRs, we were not able to determine whether data synthesis and analysis methods have been followed in advance, which may ignore the results of some studies. The robustness of the findings should be assessed through funnel plot or sensitivity analyses, and the biases in primary studies should be minimized or addressed in the synthesis.

The PRISMA-A statement provided the basis for the author to improve the reporting quality of the SRs with acupuncture as intervention. According to the results of the PRISMA score, the lowest report rate (13.33%) was in the protocol and registration section. Only 2 SRs managed to offer a protocol or registration number of SR. An advance registration helps promote transparency, minimize potential bias in the conducting and reporting review, reduce duplication of effort between groups, and keep SRs updated. \[[@B39]\] A free and open database, the International Prospective Register of Systematic Reviews (PROSPERO, <http://www.crd.york.ac.uk/prospero>), has been advocated and recommended for reviewers to avoid bringing bias in SRs. In order to achieve a better quality of evidence, the researchers need to strictly control the risk of bias with reference to the ROBIS tool when conducting SRs/meta-analyses. In accordance with the requirements of the PRISMA-A statement, writing a SR/meta-analysis helps to get better reporting quality.

In the assessment of evidence quality with GRADE tool, we found that the biggest reason for downgrading was inconsistencies among studies, owing to the high I^2^ value and statistically significant heterogeneity of effect estimates. The GRADE guideline suggests, when it comes to inconsistency, SR authors should generate and test a small number of a priori hypotheses related to patients, interventions, outcomes, and methodology to explore the sources of heterogeneity \[[@B40]\].

4.3. Strength and Limitations {#sec4.3}
-----------------------------

There are some strength in our study; firstly, this overview is the first to systematically evaluated the methodological quality and reporting quality of SRs in acupuncture for migraine. Secondly, we combined the latest high-quality evidence of SRs to provide a more convinced evidence for clinical work. Thirdly, we started this overview with a predesigned protocol, which helped reduce the risk of bias.

In addition to the strengths, there are several limitations to be noted. Firstly, there might be some missing information since we only gathered studies in English and Chinese. Secondly, we were unable to synthesize all the evidence, which may decrease the accuracy of the conclusions.

5. Conclusions {#sec5}
==============

Based on high quality of evidence, we conclude that acupuncture is more effective and safer than medication or sham acupuncture in the treatment of migraine. However, the methodological quality, risk of bias, and reporting quality of SRs in acupuncture for migraine still needs improvement in future.
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###### 

Characteristics of included SRs.

  First author and year of publication   Included study design   No. of study   No. of patient   Diagnostic criteria   Intervention                             Comparator                                                                                          Outcomes                                                                                                           Assessment of methodological quality   Meta-analysis conducted?   Subgroup analysis conducted?   Sensitivity analysis conducted?   Safety
  -------------------------------------- ----------------------- -------------- ---------------- --------------------- ---------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------- -------------------------- ------------------------------ --------------------------------- --------
  Gao (2011)                             RCT                     12             1744             IHS; ICHD-10          Acupuncture                              Sham acupuncture                                                                                    Effective rate; headache days                                                                                      Jadad scale                            Yes                        Yes                            No                                NR
  Zheng (2012)                           RCT                     33             3593             NR                    Acupuncture                              Herbs; sham acupuncture                                                                             Effective rate                                                                                                     Cochrane risk of bias tool             Yes                        Yes                            No                                NR
  Chen (2014)                            RCT                     18             1672             IHS                   Acupuncture                              Medications (flunarizine, ibuprofen, nimodipine, naproxen, ergotamine caffeine); herbs              Effective rate; headache frequency; headache intensity and duration; accompanying symptoms                         Cochrane risk of bias tool             Yes                        Yes                            Yes                               Yes
  Yang (2014)                            RCT                     10             893              NR                    Acupuncture                              Flunarizine                                                                                         Short-term effect; long-term effect; headache score                                                                NR                                     Yes                        No                             No                                Yes
  Zhao (2014)                            RCT                     17             1719             NR                    EA                                       Medications                                                                                         Effective rate; VAS                                                                                                Cochrane risk of bias tool             Yes                        Yes                            No                                Yes
  Dai (2015)                             RCT                     2              140              IHS                   Acupuncture                              Medications (flunarizine, nimodipine)                                                               Cure rate; effective rate                                                                                          Jadad scale                            Yes                        No                             No                                NR
  Yang (2015)                            RCT                     10             997              IHS                   Acupuncture                              Sham acupuncture                                                                                    Effective rate; headache intensity; headache frequency; headache duration; medication use; accompanying symptoms   Cochrane risk of bias tool             Yes                        Yes                            No                                Yes
  Linde (2016)                           RCT                     22             4985             IHS                   Acupuncture                              Sham interventions; medications (metoprolol, flunarizine, valproic acid); waiting list              Headache frequency; the proportion of "responders"                                                                 Cochrane risk of bias tool             Yes                        Yes                            No                                NR
  Pu J (2016)                            RCT                     5              618              NR                    Acupuncture                              Sham acupuncture                                                                                    VAS                                                                                                                Cochrane risk of bias tool             Yes                        No                             No                                No
  Pu (2016)                              RCT                     7              1285             IHS                   Acupuncture                              Medications (flunarizine, valproate, topiramate, metoprolol)                                        Effective rate; headache frequency; headache intensity; medication use                                             Cochrane risk of bias tool             Yes                        No                             Yes                               Yes
  Song (2016)                            RCT                     18             1470             IHS; ICHD             Acupuncture; EA                          Medications (flunarizine, ibuprofen, nimodipine, metoprolol); placebo                               Long-term effective rate; short-term effective rate; headache days                                                 Cochrane risk of bias tool             Yes                        Yes                            Yes                               Yes
  Xian (2016)                            RCT                     26             3657             IHS; ICHD             Acupuncture                              Sham acupuncture; medications (flunarizine, sodium valproate, metoprolol, topiramate, nimodipine)   Effective rate; headache frequency; VAS; medication use; PDI; MIDAS; PF-SF36; MH-SF36                              Cochrane risk of bias tool                                        Yes                            No                                Yes
  Zhao (2016)                            RCT                     18             1268             IHS                   Acupuncture; auricular acupuncture; EA   Medications (celecoxib, flunarizine, aspirin, ibuprofen, somedon); herbs                            Effective rate; VAS; headache intensity; headache frequency                                                        Cochrane risk of bias tool                                        Yes                            Yes                               Yes
  Xu (2018)                              RCT                     14             1155             ICHD                  Acupuncture; EA                          Medications (ergotamine, ibuprofen, flunarizine, nimodipine); sham acupuncture                      Frequency of migraine attacks; number of migraine days; VAS; effective rate                                        Cochrane risk of bias tool             Yes                        No                             No                                Yes
  Lu (2019)                              RCT                     17             2226             ICHD-3                Acupuncture; EA                          Sham acupuncture; medications (ergotamine, flunarizine, nimodipine)                                 Frequency of migraine attacks; duration of migraine; headache intensity                                            Cochrane risk of bias tool             Yes                        Yes                            Yes                               NR

IHS = International Headache Society; ICHD = International Classification of Headache Disorders; NR = no report; AA = auricular acupuncture; EA = electro-acupuncture; acupuncture = classical manual acupuncture; VAS = Visual Analogue Scale/Score; PDI = Pain Disability Index; MIDAS = the Migraine Disability Assessment; SF-36/12 = Short Form 36/12 Questionnaire.

###### 

Methodological quality of included SRs on acupuncture for migraine.

  Author (year)   I1   I2^*∗*^   I3   I4^*∗*^   I5   I6   I7^*∗*^   I8   I9^*∗*^   I10   I11^*∗*^   I12   I13^*∗*^   I14   I15^*∗*^   I16   Ranking of quality
  --------------- ---- --------- ---- --------- ---- ---- --------- ---- --------- ----- ---------- ----- ---------- ----- ---------- ----- --------------------
  Gao (2011)      Y    N         N    PY        N    N    N         Y    Y         N     N          Y     Y          N     Y          N     Critically low
  Zheng (2012)    Y    N         N    PY        Y    Y    N         N    Y         N     N          Y     Y          N     N          N     Critically low
  Chen (2014)     Y    N         N    PY        Y    Y    N         PY   Y         N     Y          Y     Y          N     Y          N     Critically low
  Yang (2014)     Y    N         N    PY        Y    N    N         PY   Y         N     N          N     N          N     N          N     Critically low
  Zhao (2014)     Y    N         N    PY        Y    Y    N         PY   Y         Y     Y          N     N          N     N          N     Critically low
  Dai (2015)      N    N         N    PY        N    N    N         N    Y         N     N          N     N          Y     N          N     Critically low
  Yang (2015)     Y    N         N    PY        N    Y    N         PY   Y         N     Y          Y     Y          Y     N          N     Critically low
  Linde (2016)    Y    N         N    PY        Y    Y    N         PY   Y         N     Y          Y     Y          N     N          N     Critically low
  PuJ (2016)      Y    N         N    PY        Y    Y    N         N    Y         N     Y          N     N          Y     N          N     Critically low
  Pu (2016)       Y    N         N    PY        Y    Y    N         Y    Y         N     Y          Y     N          Y     N          N     Critically low
  Song (2016)     Y    N         N    N         Y    Y    N         PY   Y         N     Y          Y     N          Y     Y          N     Critically low
  Xian (2016)     Y    N         N    PY        Y    Y    N         Y    Y         N     Y          N     N          Y     N          N     Critically low
  Zhao (2016)     Y    N         N    PY        Y    Y    N         Y    Y         Y     Y          Y     Y          N     Y          N     Critically low
  Xu (2018)       Y    Y         N    PY        Y    Y    N         Y    Y         N     Y          N     Y          Y     Y          Y     Low
  Lu (2019)       Y    N         N    PY        Y    Y    N         Y    Y         N     Y          N     Y          Y     Y          N     Critically low

^*∗*^The key items of the AMSTAR 2; I: item; Y: yes; N: no; PY: partial yes. Item 1: did the research questions and inclusion criteria for the review include the components of PICO? Item 2: did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? Item 3: did the review authors explain their selection of the study designs for inclusion in the review? Item 4: did the review authors use a comprehensive literature search strategy? Item 5: did the review authors perform study selection in duplicate? Item 6: did the review authors perform data extraction in duplicate? Item 7: did the review authors provide a list of excluded studies and justify the exclusions? Item 8: did the review authors describe the included studies in adequate detail? Item 9: did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? Item 10: did the review authors report on the sources of funding for the studies included in the review? Item 11: if meta-analysis was performed did the review authors use appropriate methods for statistical combination of results? Item 12: if meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? Item 13: did the review authors account for RoB in individual studies when interpreting/discussing the results of the review? Item 14: did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? Item 15: if they performed quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? Item 16: did the review authors report any potential sources of conflicts of interest, including any funding they received for conducting the review?

###### 

Tabular presentation of risk of bias of included SRs.

  Review         Phase 2   Phase 3           
  -------------- --------- --------- --- --- ---
  Gao (2011)     ☺         ☹         ?   ☺   ☹
  Zheng (2012)   ☺         ☺         ☺   ☹   ☹
  Chen (2014)    ☺         ☺         ☺   ☺   ☺
  Yang (2014)    ☺         ☹         ☹   ☹   ☹
  Zhao (2014)    ☹         ☹         ☺   ☺   ☹
  Dai (2015)     ☺         ☹         ☹   ☹   ☹
  Yang (2015)    ☺         ☺         ☺   ☺   ☺
  Linde (2016)   ☺         ☺         ☺   ☺   ☺
  PuJ (2016)     ☹         ☹         ☺   ☹   ☹
  Pu (2016)      ☺         ☺         ☺   ☺   ☺
  Song (2016)    ☺         ☺         ☺   ☺   ☺
  Xian (2016)    ☺         ☺         ☺   ☹   ☺
  Zhao (2016)    ☺         ☺         ☺   ☺   ☺
  Xu (2018)      ☺         ☺         ☺   ☹   ☺
  Lu (2019)      ☺         ☺         ☺   ☹   ☺

☺ = low risk; ☹ = high risk; ? = unclear risk.

###### 

Compliance of included SRs with PRISMA-A checklist.

       Section/topic   Gao (2011)                           Zheng (2012)   Chen (2014)   Yang (2014)   Zhao (2014)   Dai (2015)   Yang (2015)   Linde (2016)   PuJ (2016)   Pu (2016)   Song (2016)   Xian (2016)   Zhao (2016)   Xu (2018)   Lu (2019)   Compliance (%)   
  ---- --------------- ------------------------------------ -------------- ------------- ------------- ------------- ------------ ------------- -------------- ------------ ----------- ------------- ------------- ------------- ----------- ----------- ---------------- --------
  1    Title           Title                                Y              Y             Y             Y             Y            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                100.00
  2    Abstract        Structured summary                   Y              Y             Y             Y             Y            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                100.00
  3    Introduction    Rationale                            Y              Y             Y             Y             Y            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                100.00
  4                    Objectives                           Y              Y             Y             Y             Y            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                100.00
  5    Methods         Protocol and registration            N              N             N             N             N            N             N              Y            N           N             N             N             N           Y           N                13.33
  6                    Eligibility criteria                 Y              N             Y             Y             Y            N             Y              Y            Y           Y             Y             Y             Y           Y           Y                86.67
  7                    Information sources                  Y              Y             Y             N             Y            Y             Y              N            N           Y             Y             Y             Y           Y           Y                80.00
  8                    Search                               N              N             Y             N             N            N             Y              Y            N           N             N             N             Y           N           Y                33.33
  9                    Study selection                      Y              N             Y             Y             N            N             N              Y            N           Y             N             Y             N           Y           Y                53.33
  10                   Data collection process              N              Y             Y             Y             Y            N             Y              Y            Y           Y             Y             N             Y           Y           Y                80.00
  11                   Data items                           N              N             Y             Y             N            N             Y              Y            N           Y             N             Y             Y           Y           Y                60
  12                   Risk of bias in individual studies   Y              Y             Y             Y             Y            N             Y              Y            Y           Y             Y             Y             Y           Y           Y                93.33
  13                   Summary measures                     Y              Y             Y             Y             N            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                93.33
  14                   Synthesis of results                 Y              Y             Y             Y             Y            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                100.00
  15                   Risk of bias across studies          Y              N             Y             N             N            N             N              N            N           N             Y             N             Y           Y           N                33.33
  16                   Additional analyses                  Y              Y             Y             N             N            N             Y              Y            N           Y             Y             Y             Y           Y           Y                73.33
  17   Results         Study selection                      Y              N             Y             Y             N            N             N              Y            N           Y             Y             N             Y           N           N                53.33
  18                   Study characteristics                Y              N             Y             Y             Y            N             Y              Y            Y           Y             Y             Y             Y           Y           Y                86.67
  19                   Risk of bias within studies          Y              Y             Y             Y             Y            N             Y              Y            Y           Y             Y             Y             Y           Y           Y                93.33
  20                   Results of individual studies        Y              Y             Y             Y             Y            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                100.00
  21                   Synthesis of results                 Y              Y             Y             Y             Y            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                100.00
  22                   Risk of bias across studies          Y              N             Y             N             N            N             N              N            N           N             Y             N             Y           Y           N                33.33
  23                   Additional analysis                  Y              N             Y             N             N            N             Y              Y            N           Y             N             N             Y           N           Y                46.67
  24   Discussion      Summary of evidence                  Y              Y             Y             Y             Y            Y             Y              Y            Y           Y             Y             Y             Y           Y           Y                100.00
  25                   Limitations                          N              Y             Y             Y             Y            N             Y              Y            N           Y             Y             Y             Y           Y           Y                86.67
  26                   Conclusions                          Y              Y             Y             Y             Y            N             Y              Y            Y           Y             Y             Y             Y           Y           Y                93.33
  27   Funding         Funding                              N              N             N             Y             N            N             N              Y            Y           N             Y             N             Y           Y           Y                46.67
                                                            77.78%         59.26%        92.59%        74.07%        59.26%       37.03%        77.78%         88.89%       59.26%      81.48%        81.48%        70.37%        92.59%      88.89%      88.89%            

###### 

Summary of evidence.

  Author (year)                            Outcomes (total patient number in the intervention group/total patient number in the control group or total participants in both groups, number of studies)
  ---------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Acupuncture vs sham-acupuncture          
  Gao (2011)                               Effective rate (OR = 1.28, 95% C (1.02, 1.61), *P*=0.03) (650/603, 8)
  Zheng (2012)                             Effective rate (RR = 1.87, 95% CI (1.17, 2.98), *P*=0.009) (91/54, 3)
  Chen (2014)                              Effective rate (RR = 1.19, 95% CI (1.13, 1.25), *P*=0.06), (596/438, 13); headache times (SMD = 0.75, 95% CI (0.42, 1.08), *P*=0.001), (362/288, 7); headache degree (SMD = 0.47, 95% CI (−0.17, 1.10), *P* \< 0.00001) (330/258, 6); headache duration (SMD = 0.62, 95% CI (0.46, 0.78), *P*=0.008), (362/288, 7)
  Yang (2014)                              Short-term effective rate (RR = 1.27, 95% CI (1.11, 1.45), *P* \< 0.0004), (414/409, 9); long-term effective rate (RR = 1.76, 95% CI (1.05, 2.94), *P*=0.03), (117/115, 4)
  Zhao (2014)                              Effective rate (RR = 1.18, 95% CI (1.09, 1.27), *P*=0.007) (619/410, 11)
  Dai (2015)                               Effective rate (OR = 4.85, 95% CI (1.69, 13.94), *P*=0.003), (65/51, 2)
  Yang (2015)                              Not effective rate (RR = 0.24, 95% CI (0.15, 0.38), *P*=0.61), (19/93, 4); recurrence rate (RR = 0.47, 95% CI (0.28, 0.81), *P*=93), (14/53, 2)
  Linde (2016)                             Headache frequency after treatment (SMD = −0.18, 95% CI (−0.28, −0.08), I^2^ = 47%), (952/694, 12); headache frequency after follow-up (SMD = −0.18, 95% CI (−0.28, −0.08), I^2^ = 47%), (896/638, 10)
  PuJ (2016)                               VAS score 2 h after acupuncture (MD = −0.38, 95% CI (−0.83, 0.07), *P*=0.10), (350/349, 4); reduced VAS score 2 h after acupuncture (MD = 0.36, 95% CI (0.08, 0.65), *P*=0.01), (290/289, 3); VAS score 4h after acupuncture (MD = −0.42, 95% CI (−0 .96, 0.12), *P*=0.12), (350/349, 4); reduced VAS score 4h after acupuncture (MD = 0.49, 95% CI (0.14, 0.84), *P*=0.007), (290/289, 3)
  Xian (2016)                              Effective rate at 1--2 months follow-up (RR = 1.06, 95% CI (0.92, 1.24), *P*=0.42), (508/462, 5); effective rate at 3--4 months follow-up (RR = 1.06, 95% CI (0.91, 1.22), *P*=0.48), (525/476, 6); effective rate at 5--6 months follow-up (RR = 1.11, 95% CI (0.96, 1.29), *P*=0.17), (515/470, 5); effective rate of more than 6 months follow-up (RR = 2.03, 95% CI (1.10, 3.74), *P*=0.02), (24/11, 2)
  Xu (2018)                                Headache frequency (MD = 1.05, 95% CI (1.75, 0.34); *P* \< 0.01), (120/120, 3); VAS score (MD = 1.19, 95% CI (1.75, 0.63); *P* \< 0.01), (84/84, 3)
  Lu (2019)                                Headache frequency (SMD = −0.97, 95% CI (−1.60,−0.34), *P*=0.002), (95/69, 3); headache duration (SMD = −0.73, 95% CI (−1.25,−0.21),*P*=0.006) (86/82, 3); headache intensity (SMD = −0.67, 95% CI (−1.15, −0.19),*P*=0.006), (553/490, 6)
  Acupuncture vs western medicine          
  Zheng (2012)                             Effective rate (RR = 1.24, 95% CI (1.16, 1.34), *P* \< 0.00001), (1602/925, 28)
  Linde (2016)                             Headache frequency after treatment (SMD = −0.25, 95% CI (−0.39, −0.10)), (431/308, 3); headache frequency after follow-up (SMD = −0.13, 95% CI (−0.28, −0.01)), (436/308, 3)
  Pu (2016)                                Effective rate after 3--4 months(RR = 1.24, 95% CI (1.04, 1.47), *P*=0.02), (449/323, 4); effective rate after 5--6 months (RR = 1.18, CI (0.97, 1.43), *P*=0.11), (344/220, 2); headache days after 3--4 months (SMD = -0.30, 95% CI (−0.45,−0.16), *P* \< 0.0001), (439/316, 4); headache days after 5--6 months (MD = −0.66, 95% CI (−1.18,−0.13), *P*=0.01), (344/220, 2); headache times after 3--4 months (MD = −0.32, 95% CI (−0.59,-0.04), *P*=0.03), (171/145, 3); headache times after 3--4 months (MD = −0.47, 95% CI (−1.22,−0.28), *P*=0.22), (131/106, 2); headache degree after 3--4 months (SMD = −0.11, 95% CI (−0.56, 0.33), *P*=0.01), (495/370, 4); headache degree after 5--6 months (SMD = −0.31, 95% CI (−0.47, −0.15), *P*=0.0001), (385/261, 3); Times of using painkiller after 3--4 months(MD = −0.64, 95% CI (−1.93, 0.65), *P*=0.33), (207/181, 4); times of using painkiller after 5--6 months(SMD = −0.22, 95% CI (−0.44, 0.00), *P*=0.06), (174/147, 3)
  Song (2016)                              Short-term effective rate (RR = 2.76, 95% CI (2.03, 3.77), *P* \< 0.00001), (616/602, 15); long-term effective rate(RR = 4.17, 95% CI (2.80, 6.20), *P* \< 0.00001), (331/311, 7); headache times (RR = −0.79, 95% CI (−1.39, −0.20), *P*=0.009), (92/72, 2)
  Xian (2016)                              Effective rate at 0--1 months follow-up (RR = 1.66, 95% CI (1.16, 2.37), *P*=0.005), (180/160, 4); effective rate at 1--2 months follow-up (RR = 1.25, 95% CI (1.01, 1.55), *P*=0.04), (162/76, 2); effective rate at 3--4 months follow-up (RR = 1.55, 95% CI (1.09, 2.20), *P*=0.01), (239/125, 5); effective rate at 5--6 months follow-up (RR = 1.30, 95% CI (0.77, 2.19), *P*=0.32), (169/87, 2)
  Zhao (2016)                              Effective rate (RR = 1.18, 95% CI (1.09, 1.27), *P*=0.007), (649/497, 11);
  Xu (2018)                                Headache frequency (MD = 1.50; 95% CI (2.32, 0.68); *P* \< 0.01), (110/110, 2); VAS score (MD = 0.97, 95% CI (0.63, 1.31); *P* \< 0.01), (198/163, 3); effective rate (RR = 1.30; 95% CI (1.16, 1.45); *P* \< 0.01), (178/178, 6)
  Lu (2019)                                Headache frequency (SMD = −1.29, 95% CI (−1.85,−0.73), *P* \< 0.00001), (512/486, 8); headache duration (SMD = −0.88, 95% CI (−1.32, −0.45), *P* \< 0.0001) (445/427, 7)
  Acupuncture vs Chinese herbal medicine   
  Zheng (2012)                             Effective rate (RR = 1.29, 95% CI (1.14, 1.45), *P* \< 0.00001), (111/81, 3)

CI, confidence interval; OR, odds ratio; RR, relative risk; MD, mean difference; WMD, weighted mean difference; SMD, standardized mean difference, HR, hazard ratio; VAS, visual analogue scale.

###### 

Evidence quality of included studies.

  Author (date)                                        Interventions vs comparisons                  Outcomes (number of studies)                     Risk of bias   Inconsistency   Indirection   Imprecision   Publication bias   Quality of evidence
  ---------------------------------------------------- --------------------------------------------- ------------------------------------------------ -------------- --------------- ------------- ------------- ------------------ ---------------------
  Gao (2011)                                           Acupuncture vs sham acupuncture               Effective rate at the end of treatment (8)       0              0               0             −1^①^         0                  Moderate
  Effective rate at the end of follow-up (4)           0                                             −1^②^                                            0              −1^①^           0             Low                              
  Zheng (2012)                                         Acupuncture vs western medicine               Effective rate (8)                               0              −1^②^           0             0             0                  Low
  Acupuncture vs Chinese medicine therapy              Effective rate (3)                            0                                                0              0               −1^①^         −1^③^         Low                
  Acupuncture vs sham acupuncture                      Effective rate (3)                            0                                                0              0               −1^①^         −1^③^         Low                
  Chen (2014)                                          Acupuncture vs western medicine               Effective rate (13)                              0              0               0             0             0                  High
  Yang (2014)                                          Acupuncture vs western medicine               Short-term effective rate (9)                    0              −1^②^           0             0             0                  Low
  Long-term effective rate (4)                         0                                             −1^②^                                            0              ---1^①^         0             Very low                         
  Zhao (2014)                                          Acupuncture vs Western medicine               Effective rate (11)                              0              0               0             0             0                  High
  Dai (2014)                                           Acupuncture vs western medicine               Effective rate (2)                               0              −1^②^           0             −1^①^         −1^③^              Very low
  Pu (2016)                                            Acupuncture vs western medicine               Effective rate after 3--4 months follow-up (4)   0              −1^②^           0             −1^①^         −1^③^              Very low
  Effective rate after 5--6 months follow-up (2)       0                                             0                                                0              −1^①^           −1^③^         Low                              
  Song (2016)                                          Acupuncture vs western medicine               Short-term effective rate (15)                   0              0               0             0             0                  High
  Long-term effective rate (7)                         0                                             0                                                0              0               0             High                             
  Long-term headache times (2)                         0                                             −1^②^                                            0              0               −1^③^         Low                              
  Xian (2016)                                          Acupuncture vs sham acupuncture               Effective rate at 1--2 months follow-up (5)      0              0               0             −1^①^         0                  Moderate
  Effective rate at 3--4 months follow-up (6)          0                                             0                                                0              −1^①^           0             Moderate                         
  Effective rate at 5--6 months follow-up (5)          0                                             −1^②^                                            0              −1^①^           0             Low                              
  Effective rate of more than 6 months follow-up (2)   0                                             −1^②^                                            0              0               −1^③^         Low                              
  Acupuncture vs western medicine                      Effective rate at 1--2 months follow-up (4)   0                                                −1^②^          0               0             −1^③^         Low                
  Effective rate at 3--4 months follow-up (2)          0                                             −1^②^                                            0              0               −1^③^         Very low                         
  Effective rate at 5--6 months follow-up (5)          0                                             −1^②^                                            0              −1^①^           −1^③^         Very low                         
  Effective rate of 0--1 months follow-up (2)          0                                             −1^②^                                            0              −1^①^           −1^③^         Very low                         
  Zhao (2016)                                          Acupuncture vs western medicine               Effective rate (8)                               0              −1^②^           0             0             0                  Moderate
  Xu (2018)                                            Acupuncture vs western medicine               Effective rate (6)                               0              0               0             −1^①^         0                  Moderate

^①^The optimal information size was not enough. ^②^I^2^ value of the combined results was large, and/or confidence intervals overlapped difference. ^③^Suspicion of publishing bias.

[^1]: Academic Editor: Federica Galli
